Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 98% Improvement Relative Risk Hospitalization 91% Webb et al. Casirivimab/i.. for COVID-19 EARLY Favors casirivimab/im.. Favors control
Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early COVID-19
Webb et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331
Webb et al., Real-World Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients with Early.., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab331
Jun 2021   Source   PDF  
  All Studies   Meta
Retrospective 115 patients treated with casirivimab/imdevimab showing lower mortality, hospital admission, and emergency department visits with treatment. Authors incorrectly state that "no other COVID-19 therapies for ambulatory patients have proven effective".
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].
risk of death, 98.3% lower, RR 0.02, p = 0.63, treatment 0 of 115 (0.0%), control 57 of 5,536 (1.0%), NNT 97, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 91.1% lower, RR 0.09, p < 0.001, treatment 1 of 115 (0.9%), control 538 of 5,536 (9.7%), NNT 11.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Webb et al., 23 Jun 2021, retrospective, USA, peer-reviewed, 14 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCasirivimab/i..All
Abstract: Open Forum Infectious Diseases MAJOR ARTICLE Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19 Brandon J. Webb,1,2, Whitney Buckel,3 Todd Vento,1 Allison M. Butler,4 Nancy Grisel,4 Samuel M. Brown,5 Ithan D. Peltan,5 Emily S. Spivak,6 Mark Shah,7 Theadora Sakata,8 Anthony Wallin,8 Eddie Stenehjem,1,2,9 Greg Poulsen,10 and Joseph Bledsoe7,11 Background. Neutralizing monoclonal antibodies (MAbs) are a promising therapy for early coronavirus disease 2019 (COVID19), but their effectiveness has not been confirmed in a real-world setting. Methods. In this quasi-experimental pre-/postimplementation study, we estimated the effectiveness of MAb treatment within 7 days of symptom onset in high-risk ambulatory adults with COVID-19. The primary outcome was a composite of emergency department visits or hospitalizations within 14 days of positive test. Secondary outcomes included adverse events and 14-day mortality. The average treatment effect in the treated for MAb therapy was estimated using inverse probability of treatment weighting and the impact of MAb implementation using propensity-weighted interrupted time series analysis. Results. Pre-implementation (July–November 2020), 7404 qualifying patients were identified. Postimplementation (December 2020–January 2021), 594 patients received MAb treatment and 5536 did not. The primary outcome occurred in 75 (12.6%) MAb recipients, 1018 (18.4%) contemporaneous controls, and 1525 (20.6%) historical controls. MAb treatment was associated with decreased likelihood of emergency care or hospitalization (odds ratio, 0.69; 95% CI, 0.60–0.79). After implementation, the weighted probability that a given patient would require an emergency department visit or hospitalization decreased significantly (0.7% per day; 95% CI, 0.03%–0.10%). Mortality was 0.2% (n = 1) in the MAb group compared with 1.0% (n = 71) and 1.0% (n = 57) in pre- and postimplementation controls, respectively. Adverse events occurred in 7 (1.2%); 2 (0.3%) were considered serious. Conclusions. MAb treatment of high-risk ambulatory patients with early COVID-19 was well tolerated and likely effective at preventing the need for subsequent emergency department or hospital care. Keywords. novel coronavirus; COVID-19; SARS-CoV-2; monoclonal antibody; casirivimab; imdevimab; bamlanivimab. Monoclonal antibodies (MAbs) designed to avidly bind to the receptor binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein are an emerging neutralizing passive immune therapy for coronavirus disease 2019 (COVID-19). In fall 2020, bamlanivimab (Eli Lilly, Indianapolis, IN, USA) and casirivimab/imdevimab (Regeneron, Tarrytown, NY, USA) received US Food and Drug Received 21 April 2021; editorial decision 17 June 2021; accepted 19 June 2021. Correspondence: Brandon J. Webb, MD, Division of Epidemiology and Infectious Diseases, Intermountain Medical Center, 5121 S. Cottonwood Drive, Murray, UT 84157 (brandon.webb@ Open Forum Infectious Diseases®2021 © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence ( by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop